What is the official website of VNS Therapy™ for Epilepsy ?

The official website of VNS Therapy™ for Epilepsy is https://www.livanova.com/epilepsy-vnstherapy/en-us/hcp.

What is VNS Therapy™ for Epilepsy's cybersecurity risk score?

VNS Therapy™ for Epilepsy has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has VNS Therapy™ for Epilepsy experienced?

According to Rankiteo, VNS Therapy™ for Epilepsy currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has VNS Therapy™ for Epilepsy been affected by any supply chain cyber incidents ?

According to Rankiteo, VNS Therapy™ for Epilepsy has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does VNS Therapy™ for Epilepsy have SOC 2 Type 1 certification ?

According to Rankiteo, VNS Therapy™ for Epilepsy is not certified under SOC 2 Type 1.

Does VNS Therapy™ for Epilepsy have SOC 2 Type 2 certification ?

According to Rankiteo, VNS Therapy™ for Epilepsy does not hold a SOC 2 Type 2 certification.

Does VNS Therapy™ for Epilepsy comply with GDPR ?

According to Rankiteo, VNS Therapy™ for Epilepsy is not listed as GDPR compliant.

Does VNS Therapy™ for Epilepsy have PCI DSS certification ?

According to Rankiteo, VNS Therapy™ for Epilepsy does not currently maintain PCI DSS compliance.

Does VNS Therapy™ for Epilepsy comply with HIPAA ?

According to Rankiteo, VNS Therapy™ for Epilepsy is not compliant with HIPAA regulations.

Does VNS Therapy™ for Epilepsy have ISO 27001 certification ?

According to Rankiteo,VNS Therapy™ for Epilepsy is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does VNS Therapy™ for Epilepsy operate in ?

VNS Therapy™ for Epilepsy operates primarily in the Medical Device industry.

How many employees does VNS Therapy™ for Epilepsy have ?

VNS Therapy™ for Epilepsy employs approximately 9 people worldwide.

Does VNS Therapy™ for Epilepsy own any subsidiaries ?

VNS Therapy™ for Epilepsy presently has no subsidiaries across any sectors.

How many LinkedIn followers does VNS Therapy™ for Epilepsy have ?

VNS Therapy™ for Epilepsy's official LinkedIn profile has approximately 4,847 followers.

Does VNS Therapy™ for Epilepsy have a Crunchbase profile ?

No, VNS Therapy™ for Epilepsy does not have a profile on Crunchbase.

Does VNS Therapy™ for Epilepsy have a LinkedIn profile ?

Yes, VNS Therapy™ for Epilepsy maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/vnstherapy.

How many cybersecurity incidents has VNS Therapy™ for Epilepsy experienced ?

As of July 3, 2026, Rankiteo reports that VNS Therapy™ for Epilepsy has not experienced any cybersecurity incidents.

How many peer or competitor companies does VNS Therapy™ for Epilepsy have ?

VNS Therapy™ for Epilepsy has an estimated 1,513 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

VTE

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

VNS Therapy™ for Epilepsy Vendor Cyber Rating & Cyber Score

livanova.com

Add Your Compliance Badge

VNS Therapy™ is a medical device proven to treat difficult-to-control seizures, also known as drug-resistant epilepsy. The device sends mild pulses through the vagus nerve to areas of the brain known to be associated with seizures. More than 125,000 people worldwide have received VNS Therapy as a treatment for drug-resistant epilepsy, including over 30,000 children. INTENDED USE/INDICATIONS-UNITED STATES VNS Therapy is indicated for use as an adjunctive therapy in reducing the frequency of seizures in people over 4 years of age with partial onset seizures that are refractory to antiepileptic medications. ADVERSE EVENTS The most commonly reported side effects from stimulation include hoarseness (voice alteration), paresthesia

VTE A.I CyberSecurity Scoring

Scoring History

VTE

VNS Therapy™ for Epilepsy CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

VTE Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for VTE

Incidents vs Medical Device Industry Avg (This Year)

No incidents recorded for VNS Therapy™ for Epilepsy in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for VNS Therapy™ for Epilepsy in 2026.

Incident Types VTE vs Medical Device Industry Avg (This Year)

No incidents recorded for VNS Therapy™ for Epilepsy in 2026.

Incident History - VTE (X = Date, Y = Severity)

Loading…

SUBSIDIARY

VNS Therapy™ for Epilepsy Subsidiaries

Parent Company

VTE

Medical Device

Website: https://www.livanova.com/epilepsy-vnstherapy/en-us/hcp

Company Size: 1,001-5,000 employees

No subsidiary data available for this company.

Loading…

VNS Therapy™ for Epilepsy Similar Companies

Dentsply Sirona

dentsplysirona.com

A Global Total Solutions Provider Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, empowering dental professionals to provide better, safer and faster dental care. Our products and solutions include leading positions and platforms across consumables, equipment, technology, and specialty products. Dentsply Sirona is one global team that brings out the best in our people, lives and breathes high performance and personal accountability, acts with uncompromising integrity, improves the practice of dentistry with an unrelenting commitment to our customers and demonstrates a passion for innovation that shapes the dental industry. As The Dental Solutions Company™ Dentsply Sirona’s comprehensive solutions offering includes leading product brands across consumables, equipment, technology and specialty products. With the broadest clinical education platform and an unparalleled commitment to R&D in dentistry, our mission and vision guide us to continuously aim higher, support our customers and advance patient care around the world. Dentsply Sirona’s Global Headquarters is located in Charlotte, North Carolina. Our shares are listed in the United States on NASDAQ under the symbol XRAY. We care about your privacy - you can view our Privacy Policy here: http://www.dentsplysirona.com/privacy.

Loading…

NEWS

VNS Therapy™ for Epilepsy CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

February 25, 2026 08:00 AM

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and...

Read Article

November 24, 2025 08:00 AM

LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

LONDON, November 24, 2025--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers...

Read Article

June 05, 2025 07:00 AM

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures.

Read Article

April 25, 2025 01:30 AM

LIVN Stock Price, News & Analysis

LivaNova PLC (LIVN) is a London‑based global medical technology company focused on neurological and cardiac conditions, including epilepsy and...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-57100

SUMMARY

Server-side request forgery (ssrf) in Microsoft Entra Provisioning Service (SyncFabric) allows an authorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 9.9)

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

Impact Score

Exploitability

3.1

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-57100

CVE-2026-54998

SUMMARY

Incorrect authorization in Microsoft Exchange Online allows an authorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-54998

CVE-2026-45499

SUMMARY

Server-side request forgery (ssrf) in Azure OpenAI allows an authorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 9.9)

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

Impact Score

Exploitability

3.1

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-45499

CVE-2026-41106

SUMMARY

Url redirection to untrusted site ('open redirect') in M365 Copilot allows an unauthorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 9.3)

cvss3

Base Score: 9.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:N

Impact Score

5.8

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-41106

CVE-2026-26145

SUMMARY

Improper access control in Azure Synapse allows an authorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 4.8)

cvss3

Base Score: 4.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.2

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-26145

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…